VA
FPRX

VR Adviser’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

VR Adviser’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-245,122
Closed -$4.17M – 32
2020
Q4 		$4.17M Buy
+245,122
New +$3.07M 0.61% 22

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VR Adviser's FPRX Position: Q1 2021 in Review

VR Adviser sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 245,122 shares — an estimated $4.17M sold.

VR Adviser first reported a position in FPRX in Q4 2020 and held it in 1 quarter. The position peaked at $4.17M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • VR Adviser reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • VR Adviser sold 245,122 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $4.17M.
  • VR Adviser first reported a position in Five Prime Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • VR Adviser's Five Prime Therapeutics, Inc. position peaked at $4.17M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on VR Adviser's 13F filing for Q1 2021, filed 14 May 2021.